Parva Yogeshchandra Purohit,Paras Rasiklal Vasanani,Vikas Maheshbhai Agrawal,Kishan Pradipbhai Suchak
申请号：
US16637422
公开号：
US20200197366A1
申请日:
2018.08.06
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present invention relates to a pharmaceutical composition comprising glucosylceramide synthase inhibitor and a one or more pharmaceutically acceptable excipients. The present invention specifically relates to a sublingual pharmaceutical composition of eliglustat or a pharmaceutically acceptable salt thereof and a one or more pharmaceutically acceptable excipients. Moreover, the present invention further relates to a pharmaceutical composition of eliglustat or a pharmaceutically acceptable salt thereof which is used in the treatment of individual with lysozymal storage diseases selected from the group consisting of, Gaucher disease, Sphingolipidoses, Farber disease, Krabbe disease, Fabry disease, Schindler disease, Tay-Sachs disease and Niemann-Pick disease.
